Memory markers in the continuum of the Alzheimer's clinical syndrome

Alzheimers Res Ther. 2022 Sep 30;14(1):142. doi: 10.1186/s13195-022-01082-9.

Abstract

Background: The individual and complementary value of the Visual Short-Term Memory Binding Test (VSTMBT) and the Free and Cued Selective Reminding Test (FCSRT) as markers to trace the AD continuum was investigated. It was hypothesised that the VSTMBT would be an early indicator while the FCSRT would inform on imminent progression.

Methods: Healthy older adults (n=70) and patients with mild cognitive impairment (MCI) (n=80) were recruited and followed up between 2012 and 2017. Participants with at least two assessment points entered the study. Using baseline and follow-up assessments four groups were defined: Older adults who were healthy (HOA), with very mild cognitive but not functional impairment (eMCI), and with MCI who did and did not convert to dementia (MCI converters and non-converters).

Results: Only the VSTMBT predicted group membership in the very early stages (HOA vs eMCI). As the disease progressed, the FCSRT became a strong predictor excluding the VSTMB from the models. Their complementary value was high during the mid-prodromal stages and decreased in stages closer to dementia.

Discussion: The study supports the notion that neuropsychological assessment for AD needs to abandon the notion of one-size-fits-all. A memory toolkit for AD needs to consider tools that are early indicators and tools that suggest imminent progression. The VSTMBT and the FSCRT are such tools.

Keywords: Alzheimer’s disease; Early detection; Neuropsychological assessment; Visual Short-Term Memory Binding.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease* / diagnosis
  • Alzheimer Disease* / psychology
  • Aniline Compounds
  • Biomarkers
  • Cognitive Dysfunction* / diagnosis
  • Disease Progression
  • Humans
  • Neuropsychological Tests

Substances

  • Aniline Compounds
  • Biomarkers